The proposed sale is small and routine for an insider with RSU vesting. Monitor for actual sale execution on Form 4, but no immediate catalyst. The 10b5-1 plan suggests the sale is pre-planned and not opportunistic.
Price Chart
Executive Summary
Fred Aslan, a Director and Officer of Artiva Biotherapeutics, filed a Form 144 notice of intent to sell 34,465 shares of common stock, with an estimated aggregate market value of approximately $245,735. The shares were acquired via vesting of restricted stock units between August 2025 and October 2026. The proposed sale is relatively small relative to the issuer's market cap and appears to be a routine diversification move, not a signal of distress.
Key Facts
- Fred Aslan (Director and Officer) filed Form 144 to sell 34,465 shares of common stock.
- Estimated aggregate market value of the proposed sale is approximately $245,735.
- Shares were acquired upon vesting of restricted stock units from August 2025 through October 2026.
- The filing is an advance notice of intent to sell; the sale may or may not occur.
- The filing references a 10b5-1 trading plan for the seller.
Financial Impact
Proposed sale of 34,465 shares valued at ~$245,735, which is a small fraction of the issuer's market cap.
Risk Factors
- Insider selling, even if pre-planned, can be perceived negatively by the market if the stock is under pressure.
- The filing does not disclose the exact number of shares held by the insider, so the proportional impact is unclear.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010072 |
| Document: 0001950047-26-010072-index.html | 0001950047-26-010072 |
| Document: 0001950047-26-010072.txt | 0001950047-26-010072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 2d ago | 8-K | $4.27 | awaiting T+20 | awaiting T+20 | $4.20 (+1.52%) |
Oct 6, 2026 22d ago | 144 | $7.00 | awaiting T+20 | awaiting T+20 | $4.20 (−39.93%) |
Sep 11, 2026 6w ago | 8-K | $10.14 $6.77 | ▼ −33.23% | ▼ −35.50% | $4.20 (−58.53%) |
Sep 9, 2026 7w ago | Insider Cluster | $10.42 $6.80 | ▼ −34.74% | ▼ −37.12% | $4.20 (−59.64%) |
Sep 9, 2026 7w ago | Insider Cluster | $10.42 $6.80 | ▼ −34.74% | ▼ −37.12% | $4.20 (−59.64%) |
Sep 9, 2026 7w ago | Insider Cluster | $10.42 $6.80 | ▼ −34.74% | ▼ −37.12% | $4.20 (−59.64%) |
Sep 9, 2026 7w ago | Insider Cluster | $10.42 $6.80 | ▼ −34.74% | ▼ −37.12% | $4.20 (−59.64%) |
Sep 9, 2026 7w ago | Insider Cluster | $10.42 $6.80 | ▲ +34.74% | ▲ +37.12% | $4.20 (+59.64%) |
Sep 4, 2026 7w ago | Insider Cluster | $10.88 $7.27 | ▼ −33.18% | ▼ −35.15% | $4.20 (−61.35%) |
Sep 4, 2026 7w ago | Insider Cluster | $10.88 $7.27 | ▲ +33.18% | ▲ +34.89% | $4.20 (+61.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers